Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection

被引:30
作者
Alvarez-Uria, Gerardo [1 ,2 ]
Day, Jeremy N. [1 ,3 ]
Nasir, Anisa J. [1 ]
Russell, Susan K. [1 ]
Vilar, Francisco Javier [1 ]
机构
[1] N Manchester Grp Hosp, Dept Infect Dis, Monsall Unit, Manchester M8 5RB, Lancs, England
[2] Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain
[3] Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam
关键词
antidepressive agents; depression; liver cirrhosis; peginterferon; psychotic disorders; PEGYLATED INTERFERON-ALPHA; VIRUS-INFECTION; US VETERANS; ANTIVIRAL THERAPY; DEPRESSION; RIBAVIRIN; PREVALENCE; PREVENTION; PSYCHOSIS; OUTCOMES;
D O I
10.1111/j.1478-3231.2008.01958.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background Genotype 2/3 hepatitis C virus (HCV) has a good response to treatment with peginterferon and ribavirin. Patients with psychiatric disorders and injecting drug users (IDUs) are considered 'difficult to treat' and are often excluded from treatment despite the lack of evidence supporting this decision. Aims To investigate the outcome and factors associated with treatment failure in these groups. Methods This is an observational study of a cohort of patients infected by genotype 2/3 HCV. IDUs and patients with psychiatric diseases were not excluded from treatment. We performed an intention-to-treat analysis to evaluate factors related to treatment failure. Results A sustained virological response (SVR) was achieved in 91 of the 125 patients treated (72.8%). Patients with chronic psychotic disorders or former IDUs had SVR rates similar to other groups. After multivariate analysis, independent factors associated with treatment failure were liver cirrhosis [odds ratio (OR) 3.4, 95% confidence interval (CI) 1.1-10.4], a history of depression and not being on antidepressants at the commencement of HCV treatment (OR 4.4, 95% CI 1.2-16) and active IDUs (OR 7.3, 95% CI 1.77-30.4). Conclusions Patients with a history of depression who were not receiving antidepressants and active IDUs are more likely to fail treatment for genotype 2/3 HCV and will need additional support.
引用
收藏
页码:1051 / 1055
页数:5
相关论文
共 28 条
[1]
Global estimates of prevalence of HCV infection among injecting drug users [J].
Aceijas, Carmen ;
Rhodes, Tim .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) :352-358
[2]
High frequency of unrecognized mental disorders in HCV-infected patients [J].
Batista-Neves, Susana Carolina ;
Quarantini, Lucas C. ;
de Almeida, Amanda Galvao ;
Bressan, Rodrigo A. ;
Lacerda, Acioly Luiz ;
de-Oliveira, Irismar R. ;
Parana, Raymundo ;
Miranda-Scippa, Angela .
GENERAL HOSPITAL PSYCHIATRY, 2008, 30 (01) :80-82
[3]
Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection [J].
Bini, EJ ;
Bräu, N ;
Currie, S ;
Shen, H ;
Anand, BS ;
Hu, KQ ;
Jeffers, L ;
Ho, SB ;
Johnson, D ;
Schmidt, WN ;
King, P ;
Cheung, R ;
Morgan, TR ;
Awad, J ;
Pedrosa, M ;
Chang, KM ;
Aytaman, A ;
Simon, F ;
Hagedorn, C ;
Moseley, R ;
Ahmad, J ;
Mendenhall, C ;
Waters, B ;
Strader, D ;
Sasaki, AW ;
Rossi, S ;
Wright, TL .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1772-1779
[4]
An interferon-α-induced psychotic disorder in a patient with chronic hepatitis C [J].
Bozikas, V ;
Petrikis, P ;
Balla, A ;
Karavatos, A .
EUROPEAN PSYCHIATRY, 2001, 16 (02) :136-137
[5]
Follow-up studies of treatment for hepatitis C virus infection among injection drug users [J].
Dalgard, O .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S336-S338
[6]
Surprisingly small effect of antiviral treatment in patients with hepatitis C [J].
Falck-Ytter, Y ;
Kale, H ;
Mullen, KD ;
Sarbah, SA ;
Sorescu, L ;
McCullough, AJ .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (04) :288-292
[7]
Preventing relapse of major depression during interferon-α therapy for hepatitis C -: A pilot study [J].
Gleason, Ondria C. ;
Fucci, John C. ;
Yates, William R. ;
Philipsen, Michelle A. .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (10) :2557-2563
[8]
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection [J].
Grebely, Jason ;
Genoway, Krista ;
Khara, Milan ;
Duncan, Fiona ;
Viljoen, Mark ;
Elliott, Doug ;
Raffa, Jesse D. ;
DeVlaming, Stanley ;
Conwaya, Brian .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) :437-443
[9]
Trend of depression and the use of psychiatric medications in US Veterans with hepatitis C during interferon-based therapy [J].
Jakiche, Antoine ;
Paredez, Edward C. ;
Tannan, Pawan K. ;
Geppert, Cynthia ;
Sontag, Vicki L. ;
Qualls, Clifford R. ;
Blair, David A. ;
Dettmer, Elizabeth L. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (11) :2426-2433
[10]
Managing chronic hepatitis C acquired through intravenous drug use [J].
Jowett, SL ;
Agarwal, K ;
Smith, BC ;
Craig, W ;
Hewett, M ;
Bassendine, DR ;
Gilvarry, E ;
Burt, AD ;
Basendine, MF .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2001, 94 (03) :153-158